Your browser doesn't support javascript.
loading
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Speranza, Giovanna; Anderson, Larry; Chen, Alice P; Do, Khanh; Eugeni, Michelle; Weil, Marcie; Rubinstein, Larry; Majerova, Eva; Collins, Jerry; Horneffer, Yvonne; Juwara, Lamin; Zlott, Jennifer; Bishop, Rachel; Conley, Barbara A; Streicher, Howard; Tomaszewski, Joseph; Doroshow, James H; Kummar, Shivaani.
Afiliação
  • Speranza G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Do K; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Eugeni M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Weil M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rubinstein L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Majerova E; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Collins J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Horneffer Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Juwara L; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Zlott J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Bishop R; National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
  • Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Streicher H; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Tomaszewski J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. skummar@stanford.edu.
Invest New Drugs ; 36(2): 230-239, 2018 04.
Article em En | MEDLINE | ID: mdl-28808818
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Purinas / Chaperonas Moleculares / Benzodioxóis / Metabolômica Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Purinas / Chaperonas Moleculares / Benzodioxóis / Metabolômica Idioma: En Ano de publicação: 2018 Tipo de documento: Article